Mirador Capital Partners LP Purchases 956 Shares of Novartis AG (NYSE:NVS)
Mirador Capital Partners LP Purchases 956 Shares of Novartis AG (NYSE:NVS)
Mirador Capital Partners LP raised its holdings in shares of Novartis AG (NYSE:NVS – Get Rating) by 3.9% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 25,747 shares of the company's stock after acquiring an additional 956 shares during the quarter. Mirador Capital Partners LP's holdings in Novartis were worth $2,259,000 at the end of the most recent reporting period.
根據米拉多資本合夥公司提交給美國證券交易委員會的最新文件，該公司在第一季度將諾華製藥(紐約證券交易所代碼：NVS-GET評級)的股票持有量增加了3.9%。該機構投資者在本季度增持了956股後，持有該公司25,747股股票。在最近一個報告期結束時，Mirador Capital Partners LP持有的諾華公司股份價值225.9萬美元。
A number of other hedge funds and other institutional investors also recently made changes to their positions in NVS. AHL Investment Management Inc. bought a new position in Novartis in the fourth quarter valued at $25,000. Dixon Hughes Goodman Wealth Advisors LLC bought a new position in shares of Novartis in the 4th quarter valued at about $32,000. Atwood & Palmer Inc. grew its holdings in shares of Novartis by 400.0% in the 1st quarter. Atwood & Palmer Inc. now owns 375 shares of the company's stock valued at $33,000 after acquiring an additional 300 shares in the last quarter. DeDora Capital Inc. acquired a new stake in shares of Novartis in the first quarter valued at about $34,000. Finally, Allegheny Financial Group LTD bought a new stake in Novartis during the fourth quarter worth about $34,000. 9.40% of the stock is currently owned by institutional investors and hedge funds.
其他一些對衝基金和其他機構投資者最近也調整了他們在NVS的頭寸。AHL Investment Management Inc.在第四季度以25,000美元的價格購買了諾華的一個新頭寸。Dixon Hughes Goodman Wealth Advisors LLC在第四季度購買了價值約3.2萬美元的諾華新股頭寸。今年第一季度，阿特伍德-帕爾默公司持有的諾華公司股票增加了400.0%。Atwood&Palmer Inc.現在持有375股該公司股票，價值33,000美元，上個季度又購入了300股。DeDora Capital Inc.在第一季度收購了價值約3.4萬美元的諾華新股。最後，阿勒格尼金融集團有限公司在第四季度購買了諾華公司價值約3.4萬美元的新股份。該公司9.40%的股票目前由機構投資者和對衝基金持有。
Analysts Set New Price Targets
分析師設定新的價格目標
NVS has been the subject of a number of analyst reports. Morgan Stanley raised their price target on Novartis from CHF 90 to CHF 94 in a research note on Friday, May 6th. Oppenheimer lowered shares of Novartis from an "outperform" rating to a "market perform" rating in a research report on Friday, June 3rd. JPMorgan Chase & Co. lifted their price objective on shares of Novartis from CHF 80 to CHF 81 and gave the company an "underweight" rating in a research report on Wednesday, July 20th. UBS Group upped their target price on shares of Novartis from CHF 85 to CHF 88 and gave the company a "neutral" rating in a report on Wednesday, April 27th. Finally, Wolfe Research cut Novartis from an "outperform" rating to a "market perform" rating in a research report on Monday, May 9th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Novartis has an average rating of "Hold" and a consensus target price of $87.33.
NVS一直是許多分析師報告的主題。摩根士丹利在5月6日星期五的一份研究報告中將諾華的目標價從90瑞士法郎上調至94瑞士法郎。在6月3日星期五的一份研究報告中，奧本海默將諾華公司的股票評級從“跑贏大盤”下調至“市場表現”。摩根大通公司在7月20日星期三的一份研究報告中將諾華公司的股票目標價從80瑞士法郎上調至81瑞士法郎，並給予該公司“減持”評級。瑞銀集團在4月27日週三的一份報告中將諾華公司的股票目標價從85瑞士法郎上調至88瑞士法郎，並給予該公司“中性”評級。最後，沃爾夫研究公司在5月9日星期一的一份研究報告中將諾華公司的評級從“跑贏大盤”下調至“市場表現”。兩名股票研究分析師對該股的評級為賣出，八名分析師給予持有評級，三名分析師給予買入評級，一名分析師對該公司股票給予強烈買入評級。根據MarketBeat的數據，諾華的平均評級為持有，共識目標價為87.33美元。
Novartis Stock Performance
諾華公司股票表現
Novartis (NYSE:NVS – Get Rating) last released its quarterly earnings results on Monday, July 18th. The company reported $1.56 EPS for the quarter, beating the consensus estimate of $1.52 by $0.04. Novartis had a net margin of 44.31% and a return on equity of 21.88%. The business had revenue of $12.78 billion for the quarter, compared to the consensus estimate of $12.78 billion. During the same period in the prior year, the company posted $1.64 earnings per share. Novartis's revenue was down 1.4% compared to the same quarter last year. On average, equities analysts forecast that Novartis AG will post 6.06 EPS for the current year.
諾華公司(紐約證券交易所代碼：NVS-GET Rating)最近一次發佈季度收益報告是在7月18日星期一。該公司公佈本季度每股收益為1.56美元，比普遍預期的1.52美元高出0.04美元。諾華的淨利潤率為44.31%，股本回報率為21.88%。該業務本季度營收為127.8億美元，而市場普遍預期為127.8億美元。去年同期，該公司公佈的每股收益為1.64美元。與去年同期相比，諾華的營收下降了1.4%。股票分析師平均預測，諾華製藥本年度每股收益將達到6.06股。
Novartis Profile
諾華簡介
(Get Rating)
(獲取評級)
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products.
諾華製藥在全球研究、開發、製造和營銷保健品。該公司通過兩個部門運營，創新藥品和Sandoz。創新藥品部門為患者和醫療保健提供者提供處方藥。它還提供眼科、神經科學、免疫學、肝科、皮膚科、呼吸科、心血管、腎臟和新陳代謝藥物產品。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Novartis (NVS)
- These Stocks Outperformed Last Time There Was A Recession
- Does Rivian's Stock Still Have A Future?
- Use These To Find Your Stock's Support and Resistance Levels
- Is Boeing Stock is Ready for Lift-Off ?
- Elon Musk is Out, But Should You Be In Twitter Stock?
- 免費獲取StockNews.com關於諾華(Novartis)的研究報告
- 這些股票的表現優於上次衰退時的表現
- Rivian的股票還有前途嗎？
- 用這些來找出你的股票的支撐位和阻力位
- 波音股票準備好起飛了嗎？
- 埃隆·馬斯克出局了，但你應該加入推特股票嗎？
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.
接受諾華日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對諾華和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。